If you're having trouble viewing this email, you may see it online.

Share this:
Georgia Chapter | American Academy of Pediatrics

October 11, 2023

BLAST COMMUNICATION!
2023-2024 Interim COVID-19 Vaccine and Nirsevimab Borrowing Policy 

CDC has approved that the temporary authorization of bi-directional COVID-19 vaccine and nirsevimab borrowing for the 2023-2024 respiratory vaccine season.  Doses for COVID-19 and nirsevimab must be replaced within 30 days.  Attached is the bi-directional COVID-19 vaccine and nirsevimab borrowing policy, from the Georgia Department of Public Health.
For the 2023-2024 COVID-19 and Nirsevimab respiratory virus season, the Georgia Immunization Program (GIP) has adopted the Centers for Disease Control and Prevention’s (CDC’s), approved, two-way or bidirectional borrowing policy.
  • Two-way borrowing will allow providers to administer state supplied COVID-19 vaccine and nirsevimab to fully insured children and adults or to administer privately purchased COVID-19 vaccine and nirsevimab to VFC eligible children and uninsured or underinsured adults in the event there is a delay in shipment of either stock.
  • The purpose of this policy is to prevent missed COVID-19 vaccine and nirsevimab administration opportunities for both VFC/AVP-eligible and fully insured patients.
  • The amount of COVID-19 vaccine and nirsevimab that can be borrowed is not limited to a certain amount, however, as with other VFC/AVP vaccine products, the borrowing policy does not alleviate a provider’s responsibility to appropriately order, in a timely manner, enough private COVID-19 vaccine and nirsevimab to vaccinate insured patients within the practice.
  • The bidirectional COVID-19 vaccine and nirsevimab borrowing policy may not be used as a replacement system for a provider’s privately purchased vaccine inventory.
  • Providers must ensure borrowing state supplied COVID-19 vaccine and nirsevimab to immunize a fully insured patient does not prevent an eligible patient from receiving a needed COVID-19 vaccine and nirsevimab.
  • Providers agree to follow all VFC/AVP requirements, which include screening patients for eligibility at each immunization encounter and documenting their eligibility status.
The Georgia Immunization Program needs your help with estimating COVID-19 vaccine needs for VFC-eligible patients, as well as uninsured and underinsured adults!
Please click here to complete the Georgia VFC COVID-19 Pre-Order survey. 
For more information on completing the survey click here.
To find out more information about these events, please visit our website at www.gaaap.org or email Noreen Dahill at ndahill@gaaap.org.
Georgia Chapter of the American Academy of Pediatrics
1350 Spring Street | Ste 700 | Atlanta, GA 30309
phone: 404-881-5020 | fax: 404-249-9503 | www.gaaap.org

This email was sent to rwiskind@peachtreeparkpeds.com. To ensure that you continue receiving our emails, please add us to your address book or safe list.

manage your preferences | opt out using TrueRemove®.

Got this as a forward? Sign up to receive our future emails.


powered by emma